Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

• LP-184 is a next-generation DNA-damaging agent being developed for pancreatic cancer in a collaboration with Fox Chase Cancer Center • LP-184 has demonstrated significant potency across a wide range of studies, in-vitro, ex-vivo and in-vivo, and is being positioned for areas of high unmet need in genetically targeted pancreatic cancers • Pancreatic tumors with DNA-damage repair deficiencies were significantly more sensitive, by 2x, to LP-184 • Lantern’s A.I. based identification of the key gene in the drug mechanism-of-action for LP-184 was validated by leveraging gene-editing (CRISPR) technology to validate PTGR1 as a fundamental driver of tumor sensitivity and cancer cell death